CRISPR Therapeutics AG (CRSP)
55.63
-1.33
(-2.33%)
USD |
NASDAQ |
May 16, 16:00
55.99
+0.36
(+0.65%)
After-Hours: 20:00
CRISPR Therapeutics Enterprise Value: 2.729B for May 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 15, 2024 | 2.729B |
| May 14, 2024 | 2.623B |
| May 13, 2024 | 2.618B |
| May 10, 2024 | 2.237B |
| May 09, 2024 | 2.439B |
| May 08, 2024 | 2.417B |
| May 07, 2024 | 2.607B |
| May 06, 2024 | 2.737B |
| May 03, 2024 | 2.638B |
| May 02, 2024 | 2.566B |
| May 01, 2024 | 2.459B |
| April 30, 2024 | 2.390B |
| April 29, 2024 | 2.546B |
| April 26, 2024 | 2.468B |
| April 25, 2024 | 2.453B |
| April 24, 2024 | 2.616B |
| April 23, 2024 | 2.680B |
| April 22, 2024 | 2.616B |
| April 19, 2024 | 2.565B |
| April 18, 2024 | 2.659B |
| April 17, 2024 | 2.608B |
| April 16, 2024 | 2.812B |
| April 15, 2024 | 2.876B |
| April 12, 2024 | 3.042B |
| April 11, 2024 | 3.232B |
| Date | Value |
|---|---|
| April 10, 2024 | 3.133B |
| April 09, 2024 | 3.425B |
| April 08, 2024 | 3.332B |
| April 05, 2024 | 3.228B |
| April 04, 2024 | 3.411B |
| April 03, 2024 | 3.372B |
| April 02, 2024 | 3.409B |
| April 01, 2024 | 3.676B |
| March 28, 2024 | 4.083B |
| March 27, 2024 | 4.252B |
| March 26, 2024 | 4.321B |
| March 25, 2024 | 4.330B |
| March 22, 2024 | 4.375B |
| March 21, 2024 | 4.620B |
| March 20, 2024 | 4.488B |
| March 19, 2024 | 4.405B |
| March 18, 2024 | 4.363B |
| March 15, 2024 | 4.489B |
| March 14, 2024 | 4.087B |
| March 13, 2024 | 4.309B |
| March 12, 2024 | 4.351B |
| March 11, 2024 | 4.473B |
| March 08, 2024 | 4.642B |
| March 07, 2024 | 4.678B |
| March 06, 2024 | 4.795B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.107B
Minimum
Mar 16 2020
13.83B
Maximum
Jan 14 2021
3.832B
Average
2.943B
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 102.72B |
| Intellia Therapeutics Inc | 1.738B |
| Novartis AG | 226.53B |
| Regeneron Pharmaceuticals Inc | 99.25B |
| Viking Therapeutics Inc | 7.639B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -116.59M |
| Total Expenses (Quarterly) | 140.59M |
| EPS Diluted (Quarterly) | -1.43 |
| Earnings Yield | -4.84% |
| Normalized Earnings Yield | -3.469 |